Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07320508 2026-05-12

EIC-SNACC

Phase 2 Recruiting

100 enrolled

Carcinoma, Adenoid Cystic

NCT04771871 2026-05-07

TARMAC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2 Recruiting

144 enrolled

Breast

Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

51 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Phase 2 Recruiting

520 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

Phase 2 Recruiting

370 enrolled

Breast

Breast Neoplasms

NCT05862064 2025-07-16

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Phase 3 Recruiting

606 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06500208 2025-06-26

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Phase 2 Recruiting

48 enrolled

Breast

Breast Neoplasms

NCT06964906 2025-05-11

NeoHunter

Phase 2 Recruiting

140 enrolled

Breast

Breast Neoplasms

NCT06140966 2025-04-16

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2 Recruiting

54 enrolled

Plasma cell

Multiple Myeloma

NCT05024734 2025-03-11

GAIN INST

Phase 2 Recruiting

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06705127 2024-11-26

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

Phase 2 Recruiting

30 enrolled

Breast

HR-positive,HER2-negative Breast Cancer

NCT02897700 2024-04-17

COC-IDCB

Phase 1 Recruiting

300 enrolled

Breast

Breast Neoplasms

NCT05978648 2023-11-30

SMA-BC-002

Phase 2 Recruiting

116 enrolled

Breast

Breast Neoplasms

NCT06121570 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1 Recruiting

24 enrolled

Breast

Breast Neoplasms

NCT05981014 2023-08-08

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1/2 Recruiting

196 enrolled

Breast

Breast Neoplasms

NCT05883852 2023-06-27

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Phase 3 Recruiting

1,406 enrolled

Breast

HER2 Positive Early Breast Cancer

NCT05901428 2023-06-15

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Phase 3 Recruiting

1,736 enrolled

Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2 Recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05420454 2022-07-01

A Study for the Neoadjuvant Treatment of Breast Cancer

Phase 4 Recruiting

1,576 enrolled

Breast

Breast Neoplasms

NCT05420467 2022-07-01

A Study for the Adjuvant Treatment of Breast Cancer

Phase 4 Recruiting

2,413 enrolled

Breast

Breast Neoplasms

NCT04836156 2022-04-06

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Phase 1/2 Recruiting

46 enrolled

Breast

HER2-negative Early Breast Cancer

NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Phase 2/3 Recruiting

260 enrolled

Breast

HER2-negative Breast Cancer

NCT03025477 2021-02-11

CHIMOVIP

Phase 2 Recruiting

84 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

Clinical Trials

FASCINATE-N

EIC-SNACC

TARMAC

TARMAC

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

ARIADNE

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

NeoHunter

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

GAIN INST

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

COC-IDCB

SMA-BC-002

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

A Study for the Neoadjuvant Treatment of Breast Cancer

A Study for the Adjuvant Treatment of Breast Cancer

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

CHIMOVIP